ReviewFundamental & clinical pharmacology2023

Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.

Daisy Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.